Whatman Inc. (WHM.L) Provides FTA® Elute to NCRI Prostate Cancer Biomarker Study
8/27/2007 12:39:08 PM
FLORHAM PARK, N.J.--(BUSINESS WIRE)--Whatman, a global leader in separations technology, today announced that it will provide DNA collection kits based on its proprietary FTA® Elute technology for a pharmacogenotyping study looking at genetic markers in prostate cancer. The international study is part of the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial.
comments powered by